WO2000066225A1 - Contraceptive compositions containing cyclic carbamates and amide derivatives - Google Patents
Contraceptive compositions containing cyclic carbamates and amide derivatives Download PDFInfo
- Publication number
- WO2000066225A1 WO2000066225A1 PCT/US2000/011846 US0011846W WO0066225A1 WO 2000066225 A1 WO2000066225 A1 WO 2000066225A1 US 0011846 W US0011846 W US 0011846W WO 0066225 A1 WO0066225 A1 WO 0066225A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- alkyl
- phase
- daily dosage
- alkoxy
- Prior art date
Links
- 0 CC*C(*C)(c1c(NC(O*)=O)[s]c(*)c1)O Chemical compound CC*C(*C)(c1c(NC(O*)=O)[s]c(*)c1)O 0.000 description 6
- DQGAFZXPQOVNQR-UHFFFAOYSA-N O=C(C12CCCCC1)Nc1c2nc[s]1 Chemical compound O=C(C12CCCCC1)Nc1c2nc[s]1 DQGAFZXPQOVNQR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Definitions
- This invention relates to regimens of administering compounds which are antagonists of the progesterone receptor in combination with a progestin, an estrogen, or both
- Intracellular receptors form a class of structurally related genetic regulators known as "hgand dependent transcription factors" (R M Evans, Science, 240, 889, 1988)
- the steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR)
- the natural hormone, or hgand, for the PR is the steroid progesterone, but synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as kgands.
- a hgand is present in the fluid surrounding a cell, it passes through the membrane via passive diffusion, and binds to the IR to create a receptor/ligand complex This complex then translocates to the
- a compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound which inhibits the effect of the hormone is an agonist
- PR agonists are known to play an important role in the health of women
- PR agonists are used in birth control formulations, typically in the presence of an ER agonist
- ER agonists are used to treat the symptoms of menopause, but have been associated with a prohferative effect on the uterus (in non- hysterectomized women) which can lead to an increased nsk of uterine cancers
- Co- administration of a PR agonist reduces/ablates that risk PR antagonists may also be used in contraception In this context they may be administered alone (Ulmann, et al, Ann N Y Acad Sci , 261, 248, 1995), in combination with a PR agonist (Kekkonen. et al, Fertility and Sterility, 60, 610, 1993) or in combination with a partial ER antagonist such as tamoxifen (WO 96/19997 Al , July 4, 1996)
- PR antagonists may also be useful for the treatment of hormone dependent breast cancers (Horwitz, et al, Horm Cancer, 283, pub Birkhaeuser, Boston, Mass , ed Nedeckis) as well as uterine and ovarian cancers PR antagonists may also be useful for the treatment of non-malignant chronic conditions such as fibroids (Murph> , et al, J Chn Endo Metab , 76, 513, 1993) and endometriosis (Kettel, et al, Fertility and Sterility, 56, 402, 1991)
- PR antagonists may also be useful in hormone replacement therapy for post menopausal patients in combination with a partial ER antagonist such as tamoxifen (US 5719136)
- PR antagonists such as Mifep ⁇ stone have also been shown to have bone sparing effects in rodents, and as such may be useful in the treatment of osteoporosis associated with the menopause (Barengolts, et al, Bone, 17, 21, 1995)
- PR antagonists, such as mifep ⁇ stone and onap ⁇ stone have been shown to be effective in a model of hormone dependent prostate cancer, which may indicate their utility in the treatment of this condition in men (Michna, et al, Ann N Y Acad Sci , 761, 224, 1995)
- U S Patent No 5,521,166 teaches cyclo phasic hormonal regimens comprising an antiprogestin and a progestin wherein the progestin is administered in the alternating presence and absence of an antiprogestin
- the disclosed regimens also provide for use of an estrogen for a period of from 2-4 days to prevent breakthrough bleeding
- This invention provides combination therapies and dosing regimens utilizing antiprogestational agents in combination with one or more progestational agents
- This invention further provides methods of treatment and dosing regimens further utilizing in combination with these antiprogestins and progestins, an estrogen, such as ethinyl estradiol
- regimens and combinations may be administered to a mammal to induce contraception or for the treatment and/or prevention of secondary amenorrhea.
- dysfunctional bleeding uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas and adenocarcinomas of the endomet ⁇ um, ovary, breast, colon, prostate
- Additional uses of the invention include stimulation of food intake
- the uses herein for the treatment and/or prevention of the conditions or diseases desc ⁇ bed above includes the continuous administration or periodic discontinuation of administration of the invention to allow for minimization of effect dose or minimization of side effects or cyclic menstrual bleeding
- the use of this invention for contraception includes administration, preferably orally, to a female of child bearing age an antiprogestin in combination with an estrogen or progestin or both These administration regimens are preferably carried out over 28 consecutive days, with a terminal portion of the cycle containing administration of no progestins, estrogens or anti-progestins
- the progestins of these combinations may be administered alone or in combination with an estrogen for the first 14 to 24 days of the cycle, the progestins being administered at a dosage range equal in progestational activity to about 35 ⁇ g to about 150 ⁇ g levonorgestrel per day, preferably equal in activity to from about 35 ⁇ g to about 100 ⁇ g levonorgestrel per day
- An antiprogestin may then be administered alone or in combination with an estrogen for a period of 1 to 11 days to begin on an> cycle day between day 14 and 24
- the anti-pro gestin in these combinations may be administered at a dose of from about 2 ⁇ g to about 50 ⁇ g per day and the estrogen may be administered at a dose of from about 10 ⁇ g to about 35 ⁇ g per day
- a package or kit containing 28 tablets will include a placebo tablet on those days when the antiprogestin or progestin or estrogen is not administered
- the progestins of this invention may be administered alone or in combination with estrogen for the initial 18 to 21 days of a 28-day cycle, followed by administration of an antiprogestin, alone or in combination with an estrogen, for from 1 to 7 days
- the estrogen to be used in the combinations and formulations of this invention is preferably ethinyl estradiol
- Progestational agents useful with this invention include, but are not limited to, levonorgestrel, norgestrel, desogestrel, 3-ketodesogestrel, norethindrone, gestodene. norethindrone acetate, norgestimate, osaterone, cyproterone acetate, tnmegestone. dienogest, drospirenone, nomegestrol, or (17-deacetyl)norgest ⁇ mate
- the preferred progestins for use in the combinations of this invention are levonorgestrel, gestodene and tnmegestone
- Examples of orally administered regimens of this invention over a 28 day cycle include administration of a progestational agent solely for the first 21 days at a daily dose equal in progestational activity to from about 35 to about 100 ⁇ g of levonorgestrel
- An antiprogestin compound of this invention may then be administered at a daily dose of from about 2 to 50 mg from day 22 to day 24, followed by no administration or administration of a placebo for days 25 to 28 It is most preferred that the daily dosages of each relevant active ingredient be incorporated into a combined, single daily dosage unit, totaling 28 daily units per 28-day cycle
- a progestational agent may be coadministered for the first 21 days at a daily dose equal in progestational activity to from about 35 to about 150 ⁇ g levonorgestrel, preferably equal in activity to from about 35 to about 100 ⁇ g levonorgestrel, with an estrogen, such as ethinyl estradiol, at a daily dose range of from about 10 to about 35 ⁇ g
- an antiprogestin administered at a daily dose of from about 2 to 50 mg from da ⁇ 22 to da 24, followed by no administration or administration of a placebo for days 25 to 28
- Still another regimen within the scope of this invention will include coadministration from days 1 to 21 of a progestational agent, the progestational agent, preferably levonorgestrel, being administered at a daily dose equal in progestational activity to from about 35 to about 100 ⁇ g levonorgestrel, and an estrogen, such as ethinyl estradiol, at a daily dose range of from about 10 to about 35 ⁇ g
- a progestational agent preferably levonorgestrel
- an estrogen such as ethinyl estradiol
- kits or packages of pharmaceutical formulations designed for use in the regimens descnbed herein are preferably designed for daily oral administration over a 28-day cycle, preferably for one oral administration per day, and organized so as to indicate a single oral formulation or combination of oral formulations to be taken on each day of the 28-day cycle
- each kit will include oral tablets to be taken on each the days specified, preferably one oral tablet will contain each of the combined daily dosages indicated
- one 28-day kit may comp ⁇ se a) an initial phase of from 14 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 ⁇ g levonorgestrel, preferably equal in progestational activity to about 35 to about 100 ⁇ g levonorgestrel, b) a second phase of from 1 to 11 daily dosage units of an antiprogestin compound of this invention, each daily dosage unit containing an antiprogestin compound at a daily dosage of from about 2 to 50 mg, and c) optionally, a third phase of an orally and pharmaceutically acceptable placebo for the remaining days of the cycle in which no antiprogestin, progestin or estrogen is administered
- a preferred embodiment of this kit may comprise a) an initial phase of 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 ⁇ g levonorgestrel, preferabl> equal in progestational activity to about 35 to about 100 ⁇ g levonorgestrel. b) a second phase of 3 daily dosage units for days 22 to 24 of an antiprogestin compound of this invention, each daily dosage unit containing an antiprogestin compound at a daily dosage of from about 2 to 50 mg, and c) optionally, a third phase of 4 daily units of an orally and pharmaceutically acceptable placebo for each of days 25 to 28
- Another 28-day cycle packaging regimen or kit of this invention comp ⁇ ses a) a first phase of from 18 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 ⁇ g levonorgestrel, preferably equal in activity to from about 35 to about 100 ⁇ g levonorgestrel, and, as an estrogen, ethinyl estradiol at a daily dose range of from about 10 to about 35 ⁇ g, and b) a second phase of from 1 to 7 daily dosage units of an antiprogestin of this invention at a daily dose of from about 2 to 50 mg, and c) optionally, an orally and pharmaceutically acceptable placebo for each of the remaining 0-9 days in the 28-day cycle in which no progestational agent, estrogen or antiprogestin is administered
- a preferred embodiment of the kit desc ⁇ bed above may comp ⁇ se a) a first phase of 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 ⁇ g levonorgestrel, preferably equal in activity to from about 35 to about 100 ⁇ g levonorgestrel, and, as an estrogen ethinyl estradiol at a daily dose range of from about 10 to about 35 ⁇ g, and b) a second phase of 3 daily dosage units for days 22 to 24 of an antiprogestin administered at a daily dose of from about 2 to 50 mg, and c) optionally, a third phase of 4 daily dose units of an orally and pharmaceutically acceptable placebo for each of days 25 to 28
- a further 28-day packaged regimen or kit of this invention comprises a) a first phase of from 18 to 21 daily dosage units, each containing a progestational agent of this invention at a daily dose equal in progestational activity to about 35 to about 150 ⁇ g levonorgestre
- a prefe ⁇ ed embodiment of the package or kit just desc ⁇ bed comp ⁇ ses a) a first phase of 21 daily dosage units, each containing a progestational agent of this invention at a daily dose equal in progestational activity to about 35 to about 150 ⁇ g levonorgestrel, preferably from about 35 to about 100 ⁇ g levonorgestrel, and ethinyl estradiol at a daily dose range of from about 10 to about 35 ⁇ g, b) a second phase of 3 daily dose units for days 22 to 24, each dose unit containing an antiprogestin of this invention at a concentration of from 2 to 50 mg, and ethinyl estradiol at a concentration of from about 10 to about 35 ⁇ g, and c) optionally, a third phase of 4 daily units of an orally and pharmaceutically acceptable placebo for each of days 25 to 28 In each of the regimens and kits just desc ⁇ bed, it is preferred that the daily dosage of each pharmaceutically active component of the regimen remain fixed in each
- dosage regimens may be adjusted to provide the optimal therapeutic response
- several divided doses of each component may be administered daily or the dose may be proportionally increased or reduced as indicated by the exigencies of the therapeutic situation
- reference to a daily dosage umt may also include divided units which are administered over the course of each day of the cycle contemplated
- a and B are independent substituents selected from S. CH or N,
- A is S, B is CH or N, provided that and A and B cannot both be CH, and when A and B both equal N, one N may be optionally substituted with an Ci to C 6 alkyl group,
- Ri and R 2 are independent substituents selected from the group of H, Ci to C ⁇ alkyl, substituted Ci to C ⁇ alkyl, C 2 to C ⁇ alkenyl, substituted C 2 to C ⁇ alkenyl, C 2 to C 6 alkynyl, substituted C to C 6 alkynyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR A , or NR B COR A , or R 1 and R 2 are fused to form a) an optionally substituted 3 to 8 membered spirocyclic alkyl ring, preferably a 3 to 6 membered spirocyclic alkyl ⁇ ng, or b) an optionally substituted 3 to 8 membered spirocyclic alkenyl ⁇ ng, preferably a 3 to 6 membered spirocyclic alkenyl ⁇ ng, or
- R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted C to C 3 alkoxy, C_ to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl
- R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl
- R 3 is H, OH, NH 2 , Cj to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C 6 alkenyl, alkynyl, or substituted alkynyl, or COR c ,
- R c is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted C to C 3 alkoxy. to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl,
- R 4 is a t ⁇ substituted benzene ⁇ ng containing the substituents X, Y and Z as shown below,
- X is selected from halogen, CN, Cj to C, alkyl, substituted Ci to C-, alkyl, d to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 thioalkyl, substituted C_ to C 3 thioalkyl, Ci to C 3 aminoalkyl. substituted Ci to C ⁇ aminoalkyl, N0 2 , Ci to C 3 perfluoro alkyl, 5 or 6 membered heterocyclic ⁇ ng containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D ,
- R D is H, Ci to C 3 alkyl, substituted Cj to C 3 alkyl, aryl, substituted aryl, C to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted C t to C 3 aminoalkyl,
- R E is H, Ci to C 3 alkyl, or substituted Cj to C 3 alkyl
- Y and Z are independent independently selected from H, halogen, CN, N0 2 , Cj to C 3 alkoxy, Ci to C 3 alkyl, or d to C 3 thioalkyl, or
- R 4 is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O S, SO, S0 2 or NR 5 and containing one or two independent substituents from the group including H, halogen, CN, N0 2 and Ci to C 3 alkyl, Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, COR F , or NR G COR F , R F is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl,
- Ci to C 3 alkoxy substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl,
- R G is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl
- R 5 is H, or Ci to C 3 alkyl
- W is O or a chemical bond or a pharmaceutically acceptable salt thereof
- prefe ⁇ ed anti-pro gestational compounds for use with this invention are those of Formula I wherein A and B are independent substituents S, CH or N, provided that when A is S, B is CH or N, and when B is S, A is CH or N, and A and B cannot both be CH, and when A and B both equal N, one N may be optionally substituted with an Ci to C ⁇ alkyl group,
- R 1 is H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, CO R A , or NR B COR A ,
- R 2 is H, C] to C 6 alkyl, substituted C l to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 2 to C ⁇ alkynyl, substituted C 2 to C 6 alkynyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl.
- heterocyclic, substituted heterocyclic, COR A , or NR B COR A , or R 1 and R 2 are fused to form a) an optionally substituted 3 to 8 membered spirocyclic alkyl ⁇ ng, or b) an optionally substituted 3 to 8 membered spirocyclic alkenyl ⁇ ng, or c) an optionally substituted 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from the group of O, S and N,
- R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl. or substituted Ci to C 3 aminoalkyl,
- R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl
- R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C O alkenyl. alkynyl. or substituted alkynyl. or COR c
- R c is H, Ci to C 4 alkyl, substituted Ci to C 4 alkyl, aryl, substituted ar ⁇ l Ci to C alkoxy, substituted Ci to C 4 alkoxy, Ci to C aminoalkyl, or substituted Ci to C aminoalkyl.
- R 4 is a t ⁇ substituted benzene ring containing the substituents X, Y and Z as shown below
- X is taken from the group including halogen, CN, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to
- Ci to C 3 thioalkyl substituted Ci to C 3 thioalkyl, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5-membered heterocychc ring containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D ,
- R D is H, Ci to C alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl
- R E is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl
- Y and Z are independent substituents taken from the group including H, halogen, CN, N0 2 , Ci to C 3 alkoxy, C ⁇ to C 3 alkyl, or Ci to C 3 thioalkyl, or
- R 4 is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O S, SO, S0 2 or NR 5 and containing one or two independent substituents from the group including H, halogen, CN, N0 2 and Ci to C 3 alkyl, or Ci to C 3 alkoxy,
- R 5 is H or Ci to C 3 alkyl.
- W is O or a chemical bond or a pharmaceutically acceptable salt thereof
- progesterone receptor antagonists are those of Formula I wherein
- a and B are independent substituents from the group including S, CH or N, provided that when A is S. B is CH or N, and when B is S, A is CH or N. and A and B cannot both be CH,
- R 1 R 2 and are selected from the group which includes Ci to C 3 alkyl, substituted Ci to C 3 alkyl, or spirocyclic alkyl constructed by fusing R 1 and R 2 to form a 3 to 6 membered spirocyclic ⁇ ng,
- R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted Ci to C 6 alkyl, or COR c ,
- R c is H, Ci to C 4 alkyl, or d to C 4 alkoxy,
- R 4 is a disubstituted benzene ⁇ ng containing the substituents X and Y as shown below
- X is selected from the group including halogen, CN, Ci to C 3 alkoxy,
- Y is a substituent on the 4' or 5' position selected from the group of H, halogen, CN, N0 2 , Ci to C 3 alkoxy, to C 4 alkyl, or Ci to C 3 thioalkyl,
- R is a five membered ⁇ ng with the structure shown below
- R 5 is H, or Ci to C 3 alkyl, or Ci to C 4 C0 2 alkyl,
- X' is selected from halogen, CN, N0 2 , Ci to C 3 alkyl or Ci to d alkoxy, li
- Y' is H or Ci to C 4 alkyl
- R 4 is a six membered ⁇ ng with the structure
- X 2 is halogen, CN or N0 2
- W is O or a chemical bond, or a pharmaceutically acceptable salt thereof
- the anti-pro gestational compounds of this invention may contain an asymmetnc carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers While shown without respect to stereochemistry in Formula I, II, and III, the present invention includes such optical isomers and diastereomers, as well as the racemic and resolved, enantiome ⁇ cally pure R and S stereoisomers, as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof
- alkyl is used herein to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups having from one to 8 carbon atoms, preferably from 1 to 6 carbon atoms
- alkenyl is intended to include both straight- and branched-chain alkyl group having from 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms, with at least one carbon-carbon double bond
- alkynyl is intended to cover both straight- and branched-chain alkyl group having from 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms, with at least one carbon-carbon triple bond
- substituted alkyl refers to alkyl. alkenyl, and alkynyl as just described having one or more substituents from the group including halogen, CN, OH. N0 2 . amino, aryl. heterocychc, substituted aryl, substituted heterocyc c, alkoxy, aryloxy. substituted alkyloxy, alkylcarbonyl, alkylcarboxy. alkylamino, arylthio These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety
- aryl is used herein to refer to an aromatic system which may be a single ⁇ ng or multiple aromatic rings fused or linked together as such that at least one part of the fused or linked rings forms the conjugated aromatic system.
- the aryl groups include but not limited to phenyl. naphthyl, biphenyl, anthryl, tetrohydronaphthyl, phenanthryl
- substituted aryl refers to aryl as just defined having one or more substituents from the group including halogen.
- CN OH, N0 2 , amino. alkyl. cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio
- heterocyclic is used herein to describe a stable 4- to 7-membered monocyc c or a stable multicychc heterocyc c ring which is saturated, partially unsaturated, or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group including N, O, and S atoms
- the N and S atoms may be oxidized
- the heterocyclic ring also includes any multicychc ⁇ ng in which any of above defined heterocyc c rings is fused to an aryl ring
- the heterocychc rmg may be attached at any heteroatom or carbon atom provided the resultant structure is chemically stable
- Such heterocyclic groups include, for example, tetrahydrofuran.
- substituted heterocychc is used herein to describe the heterocyc c just defined having one or more substituents selected from the group which includes halogen, CN, OH, N0 2 . amino, alkyl, substituted alkyl, cycloalkyl, alkenyl. substituted alkenyl. alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy. alkylamino, or arylthio
- alkox> is used herein to refer to the OR group.
- R is alkyl or substituted alkyl
- aryloxy is used herein to refer to the OR group, where R is aryl or substituted aryl
- alkylcarbonyl is used herein to refer to the RCO group, where R is alkyl or substituted alkyl
- alkylcarboxy is used herein to refer to the COOR group, where R is alkyl or substituted alkyl
- aminoalkyl refers to both secondary and tertiary amines wherein the alkyl or substituted alkyl groups may be either same or different and the point of attachment is on the nitrogen atom
- thioalkyl is used herein to refer to the SR group, where R is alkyl or substituted alkyl
- halogen refers to CI. Br, F, and I element
- anti-pro gestin compounds of this invention can be prepared following the
- reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0°C up to the reflux temperature of the solvent and may require the presence of a base such as 4- dimethylaminopy ⁇ dine, t ⁇ ethylamine, py ⁇ dine or di-isopropyl ethylamine
- organo-metallic reagent such as a G ⁇ gnard reagent, an alkyl or aryl-zinc reagent, an alkyl or aryl lithium reagent in an inert solvent (tetrahydrofuran.
- the carbamate protecting group present m 4 may be removed under conditions appropriate for its removal to afford 6 (Scheme 2)
- a reagent such as phosgene, carbonyldiimidazole or dimethyl carbonate in an appropriate solvent (tetrahydrofuran, dichloromethane, benzene, etc ) also will provide access to 5
- compound 4 may be dehydrated to afford the isopropene derivative 7 (Scheme 3)
- Suitable conditions for the dehydration would be the use of a reagent such as acetic anhydride, methanesulfonyl chloride, p-toluenesulfonyl chloride or t ⁇ fluoromethane sulfonyl chlo ⁇ de or anhydride, in a solvent such as py ⁇ dine, tetrahydrofuran, dichloromethane or benzene
- the reaction can be earned out under an inert atmosphere (mtrogen or argon) from 0°C up to the reflux temperature of the solvent and may require the presence of a base such as 4-d ⁇ methylammopynd ⁇ ne, t ⁇ ethylamine, py ⁇ dine or di-isopropyl ethylamine Exposure of 7 to acidic conditions would then afford ring closure to give 5 Suitable conditions would be the use of
- a reagent such as an alkyl lithium or lithium amide in an inert solvent
- the amino thiophene compounds 15 are prepared according to a literature procedure (Comprehensive Heterocyclic Chemistry II A Review of the Literature 1982-1995 A R Katnsky et al , Vol 2, page 639) which involves treating a suitably substituted aromatic methyl ketone 13 with phosphorus oxychlo ⁇ de in N,N- dimethyl for amide to afford the chloro cyano olefin de ⁇ vative 14.
- Allowing 14 to react with methyl mercaptoacetate in methanol containing sodium methoxide affords the key aminothiophene carboxylate starting mate ⁇ al Reaction of the 2-am ⁇ no group with a suitable chloroformate or carbonate affords the protected amine 16 This can be accomphshed by allowing 15 to react with a chloroformate or carbonate derivative such as methyl chloroformate, ethyl chloroformate. allyl chloroformate.
- the carbamate protecting group present in 17 may be removed under conditions appropriate for its removal to afford 19 (Scheme 7)
- a reagent such as phosgene, carbonyldiimidazole or dimethyl carbonate in an appropriate solvent (tetrahydrofuran, dichloromethane. benzene, etc ) also will provide access to 18
- compound 17 may be dehydrated to afford the isopropene derivative 20 (Scheme 8)
- Suitable conditions for the dehydration would be the use of a reagent such as acetic anhydride, methanesulfonyl chloride, p-toluenesulfonyl chloride or t ⁇ fluoromethane sulfonyl chloride or anhydnde, in a solvent such as pyndine, tetrahydrofuran, dichloromethane or benzene
- the reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0°C up to the reflux temperature of the solvent and may require the presence of a base such as 4-d ⁇ methylam ⁇ nopy ⁇ d ⁇ ne, t ⁇ ethylamine, pyndine or di-isopropyl ethylamine
- Exposure of 20 to acidic conditions would then afford ring closure to give 18
- Suitable conditions would be the use
- a reagent such as an alkyl lithium or lithium amide in an inert solvent such
- Thiophene thiocyclocarbamates 26 and 27 may be obtained directly by treating 5 and 18 respectively with phosphorus pentasulfide in refluxing py ⁇ dine Alternatively 5 and 18 may be treated with Lawesson's reagent ([2,4-b ⁇ s(4-methoxyphenyl)-l,3-d ⁇ th ⁇ a-2,4- d ⁇ phosphetane-2,4-d ⁇ sulfide]) in refluxing py ⁇ dine to afford 26 and 27, respectively
- the carbamate protecting group present in compound 30 may be removed under conditions appropriate for its removal to afford compound 32 as taught by T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, second ed., Wiley-Interscience (1991). Subsequent ring closure of compound 32 with a reagent such as phosgene, carbonyl diimidazole or dimethyl carbonate in an appropriate solvent (THF, dichloromethane, benzene, etc) will also provide access to compound 31.
- a reagent such as phosgene, carbonyl diimidazole or dimethyl carbonate in an appropriate solvent (THF, dichloromethane, benzene, etc) will also provide access to compound 31.
- compound 30 is a tertiary alcohol then it may be dehydrated to afford the isopropene derivative 33.
- scheme 3 Suitable conditions for the dehydration would the use of a reagent such as acetic anhydnde, methanesulfonyl chloride, p- toluenesulfonyl chlo ⁇ de or t ⁇ fluoromethane sulfonyl chlo ⁇ de or anhydnde, in a solvent such as py ⁇ dine, THF, dichloromethane or benzene
- the reaction can be carried out under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent and may require the presence of a base such as 4- dimethylaminopy ⁇ dine, triethylamine, pyndine or di-isopropyl ethylamine Exposure of compound 33 to acidic conditions would then afford ring closure to give compound 31
- Compound 31 may then be converted into the bromide 34, scheme 15 Suitable conditions would be exposure to bromine or N-bromosuccinimide in a solvent such as dichloromethane, THF or acetic acid, the reaction can be earned out under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent in the presence of an additive such as silica gel Subsequent reaction of compound 34 with an aryl or heteroaryl boronic acid, boronic acid anhydride or tnalkyl stannane then provides access to the desired biaryl compound 35 The reaction can be carried out in a solvent such as acetone, ethanol, benzene, toluene or THF, under an inert atmosphere (nitrogen or argon) from 0 °C up to the reflux temperature of the solvent, in the presence of a palladium catalyst such as tetrak ⁇ s(t ⁇ phenylphosph ⁇ ne) palladium (0) or pal
- a reagent such as an alkyl lithium or lithium amide in an inert solvent such as THF
- the amine 37 is converted into a carbamate, such as a tert-butyl carbamate as descnbed in scheme 1 for the preparation of compound 2
- Hydrolysis of the ester 38 under basic conditions, for example lithium or sodium hydroxide in THF or methanol at room temperature then gives the acid 39
- Conversion of the acid 39 into the acid chloride 40 is accomplished under standard conditions, thionyl chloride or oxalyl chloride either neat or in the presence of a solvent such as dichloromethane and an additive such as a catalytic amount of N,N-d ⁇ methylformam ⁇ de Compound 40 is then reacted with diazomethane or t ⁇ methylsilyldiazomethane in an inert solvent such as THF or dichloromethane.
- the anti-progestin compounds of the formulations of the present invention can be used in the form of salts derived from pharmaceutically or physiological! ⁇ acceptable acids or bases
- These salts include, but are not limited to, the following salts with inorganic acids such as hydrochloric acid, sulfunc acid, nit ⁇ c acid, phospho ⁇ c acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maleic acid
- Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium in the form of esters, carbamates and other conventional "pro-drug" forms, which, when administered in such form, convert to the active moiety in vivo
- These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary ameno ⁇ hea, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas and adeno carcinomas of the endomet ⁇ um, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding
- Additional uses of the mvention include stimulation of food intake
- the combmed compounds When the combmed compounds are employed for the utilities desc ⁇ bed above, they may be combined with one or more pharmaceutically acceptable earners or excipients, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0 05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol.
- pharmaceutically acceptable earners or excipients for example, solvents, diluents and the like
- Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight
- active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes
- Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as com.
- Adjuvents customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, colonng agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA
- the preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard- filled or hquid-filled capsules Oral administration of the compounds is preferred
- active compounds may also be administered parenterally or intrapentoneally Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions In all cases, the form must be sterile and must be fluid to the extent that easy syringe ability exits It must be stable under conditions of manufacture and storage and must be preserved against the contammating action of microorganisms such as bactenal and fungi
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol (e g ,
- In-vitro potencies can be in the range 0 01nM-10,000nM In vivo potencies are anticipated to be in the range 1 mg/kg to 30 mg/kg
- the object of this assay is to determine a compound's progestational or antiprogestational potency based on its effect on PRE-luciferase reporter activity in CV-1 cells co-transfected with human PR and PRE-luciferase plasmids
- the mate ⁇ als methods used in the assay are as follows a Medium
- the growth medium was as follows DMEM (BioWhittaker) containing 10% (v/v) fetal bovine serum (heat inactivated). 0 1 mM MEM non-essential amino acids, lOOU/ml penicillin.
- the experimental medium was as follows DMEM (BioWhittaker), phenol red-free, containing 10% (v/v) charcoal-stripped fetal bovine serum (heat-inactivated). 0 1 mM MEM non-essential amino acids. lOOU/ml penicillin. lOOmg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL) b Cell culture, transfection. treatment, and luciferase assay
- Co-transfection is done using 1 2x10 7 cells, 5 mg pLEM plasmid with hPR-B inserted at Sphl and BamHl sites. 10 mg pGL3 plasmid with two PREs upstream of the luciferase sequence, and 50 mg sonicated calf thymus DNA as carrier DNA in 250 ml Electroporation is carried out at 260 V and 1,000 mF in a Biorad Gene Pulser II After electroporation.
- Each treatment consists of at least 4 replicates Log transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes Huber weighting is used to downweight the effects of outhers EC50 or IC 50 values are calculated from the retransformed values JMP software (SAS Institute, Inc ) is used for both one-way analysis of variance and non-hnear response analyses d Reference Compounds
- Progesterone and tnmegestone are reference progestins and RU486 is the reference antiprogestin All reference compounds are run in full dose-response curves and the EC5 0 or IC 50 values are calculated
- Progestational activity Compounds that increase PRE-luciferase activity significantly (p ⁇ 0 05) compared to vehicle control are considered active
- Antiprogestational activity Compounds that decrease 3 nM progesterone induced PRE-luciferase activity significant- ⁇ (p ⁇ 0 05)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000615105A JP2003518006A (en) | 1999-05-04 | 2000-05-01 | Contraceptive compositions containing cyclic carbamates and amide derivatives |
AU51251/00A AU5125100A (en) | 1999-05-04 | 2000-05-01 | Contraceptive compositions containing cyclic carbamates and amide derivatives |
CA002368779A CA2368779A1 (en) | 1999-05-04 | 2000-05-01 | Contraceptive compositions containing cyclic carbamates and amide derivatives |
MXPA01011308A MXPA01011308A (en) | 1999-05-04 | 2000-05-01 | Contraceptive compositions containing cyclic carbamates and amide derivatives. |
EP00935851A EP1173253A1 (en) | 1999-05-04 | 2000-05-01 | Contraceptive compositions containing cyclic carbamates and amide derivatives |
HK02104851.8A HK1043952A1 (en) | 1999-05-04 | 2002-06-28 | Contraceptive compositions containing cyclic carbamates and amide derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19824699P | 1999-05-04 | 1999-05-04 | |
US60/198,246 | 1999-05-04 | ||
US09/552,545 | 2000-04-19 | ||
US09/552,545 US6380178B1 (en) | 1999-05-04 | 2000-04-19 | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000066225A1 true WO2000066225A1 (en) | 2000-11-09 |
WO2000066225A8 WO2000066225A8 (en) | 2002-05-30 |
Family
ID=26893607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/011846 WO2000066225A1 (en) | 1999-05-04 | 2000-05-01 | Contraceptive compositions containing cyclic carbamates and amide derivatives |
Country Status (6)
Country | Link |
---|---|
US (1) | US6380178B1 (en) |
EP (1) | EP1173253A1 (en) |
JP (1) | JP2003518006A (en) |
CA (1) | CA2368779A1 (en) |
MX (1) | MXPA01011308A (en) |
WO (1) | WO2000066225A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002020526A2 (en) * | 2000-09-07 | 2002-03-14 | Bayer Pharmaceuticals Corporation | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
US7071205B2 (en) | 2002-10-11 | 2006-07-04 | Ligand Pharmaceuticals Incorporated | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
US7084151B2 (en) | 2002-10-11 | 2006-08-01 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6417214B1 (en) * | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
US6391907B1 (en) * | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6444668B1 (en) | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
AU2005237520B2 (en) | 2004-04-27 | 2012-01-19 | Wyeth | Purification of progesterone receptor modulators |
US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4330234A1 (en) * | 1993-09-02 | 1995-03-09 | Schering Ag | The use of progestogens and competitive progesterone antagonists for the production of pharmaceuticals for female fertility control and compositions comprising a progestogen and a competitive progesterone antagonist |
DE4344463A1 (en) * | 1993-12-22 | 1995-06-29 | Schering Ag | Combination product for contraception |
US5521166A (en) * | 1994-12-19 | 1996-05-28 | Ortho Pharmaceitical Corporation | Antiprogestin cyclophasic hormonal regimen |
WO1996015794A1 (en) * | 1994-11-22 | 1996-05-30 | Balance Pharmaceuticals, Inc. | Compositions and methods for contraception and for treatment of benign gynecological disorders |
US5693647A (en) * | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
WO1997049407A1 (en) * | 1996-06-25 | 1997-12-31 | Akzo Nobel N.V. | Progestogen-anti-progestogen regimens |
US5733902A (en) * | 1987-10-01 | 1998-03-31 | Schering Aktiengesellschaft | Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635964A (en) | 1969-02-10 | 1972-01-18 | Colgate Palmolive Co | 5-morpholinyl-2 1-benzisothiazolines |
US3917592A (en) | 1974-09-27 | 1975-11-04 | Chevron Res | Herbicidal N-haloacetyl-1,2-dihydro-4H-3,1-benzoxazine |
IT1039699B (en) | 1975-07-03 | 1979-12-10 | Prephar | SPERMICIDE COMPOSITION BASED ON BENZISOTHIAZOLIC DERIVATIVES |
EP0022317B1 (en) | 1979-06-12 | 1983-09-21 | Fujisawa Pharmaceutical Co., Ltd. | 2-oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives |
US4670566A (en) | 1979-07-12 | 1987-06-02 | A. H. Robins Company, Incorporated | 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones |
US4440785A (en) | 1980-10-30 | 1984-04-03 | A. H. Robins Company, Inc. | Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation |
US4721721A (en) | 1984-12-18 | 1988-01-26 | Rorer Pharmaceutical Corporation | 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses |
ATE67185T1 (en) | 1985-07-09 | 1991-09-15 | Pfizer | SUBSTITUTED OXINDOL-3-CARBOXAMINE AS AN ANTI-INFLAMMATORY AND PAIN RELIEF. |
US4666913A (en) | 1985-11-22 | 1987-05-19 | William H. Rorer, Inc. | Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses |
DE3633861A1 (en) | 1986-10-04 | 1988-04-07 | Thomae Gmbh Dr K | NEW IMIDAZO-BENZOXAZINONE, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
JPS63112584A (en) | 1986-10-29 | 1988-05-17 | Yoshitomi Pharmaceut Ind Ltd | Imidazopyridine derivative |
US4822794A (en) | 1987-05-08 | 1989-04-18 | Rorer Pharmaceutical Corporation | Pyridooxazinone-pyridone compounds, cardiotonic compositions including the same, and their uses |
DE3718527A1 (en) | 1987-06-03 | 1988-12-15 | Basf Ag | METHOD FOR PRODUCING 2 (5H) FURANONES |
DE3734745A1 (en) | 1987-10-09 | 1989-04-20 | Schering Ag | TETRAHYDROPYRROLO (2,1-C) (1,2,4) -THIADIAZOL-3-YLIDENIMINOBENZOXAZINONE AND OTHER HETEROCYCLICALLY SUBSTITUTED AZOLES AND AZINES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS AGENTS WITH HERBICIDES |
JPH02138183A (en) | 1988-11-17 | 1990-05-28 | Nippon Tokushu Noyaku Seizo Kk | Herbicidal pyrroles |
FR2643903A1 (en) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS |
DE3932953A1 (en) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | NEW 2-BICYCLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE3935514A1 (en) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | NEW BICYCLO IMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
KR0164842B1 (en) | 1990-03-24 | 1999-01-15 | 손정삼 | Novel benzoxazine, benzothiazine derivatives and preparation thereof |
TW203049B (en) | 1990-04-13 | 1993-04-01 | Yamanouchi Pharma Co Ltd | |
DE69132061D1 (en) | 1990-09-28 | 2000-04-20 | I F L O S A S Di Giorgio E Ald | Contraceptive and menstrual cycle-regulating preparation with oncostatic properties |
EP0510235A1 (en) | 1991-04-26 | 1992-10-28 | Dong-A Pharm. Co., Ltd. | Novel benzoxazine or benzothiazine derivatives and process for the preparation of the same |
JP3108483B2 (en) | 1991-09-30 | 2000-11-13 | 日清製粉株式会社 | Indole derivatives and anti-ulcer drugs containing the same as active ingredients |
SE9103752D0 (en) | 1991-12-18 | 1991-12-18 | Astra Ab | NEW COMPOUNDS |
GB9201038D0 (en) | 1992-01-16 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
US5808139A (en) | 1992-04-21 | 1998-09-15 | Ligand Pharmaceuticals Incorporated | Non-steroid progesterone receptor agonist and antagonist and compounds and methods |
DE4242451A1 (en) | 1992-12-16 | 1994-06-23 | Basf Ag | Process for the preparation of 5-ring heterocycles |
ZA939516B (en) | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
SE9302080D0 (en) | 1993-06-16 | 1993-06-16 | Ab Astra | NEW COMPOUNDS |
DE4335876A1 (en) | 1993-10-17 | 1995-04-20 | Schering Ag | Combination of progesterone antagonists and partial agonist antiestrogens for hormone replacement therapy for peri- and postmenopausal women |
WO1995020389A1 (en) | 1994-01-28 | 1995-08-03 | Merck & Co., Inc. | Benzoxazinones as inhibitors of hiv reverse transcriptase |
US5681817A (en) | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
US5750471A (en) | 1994-06-08 | 1998-05-12 | E. I. Du Pont De Nemours And Company | Cyclic sulfonamide herbicides |
EP1382597A3 (en) | 1994-12-22 | 2004-04-07 | Ligand Pharmaceuticals, Inc. | Steroid receptor modulator compounds and methods |
ZA9510926B (en) | 1994-12-23 | 1996-07-03 | Schering Ag | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
WO1997013767A1 (en) | 1995-10-09 | 1997-04-17 | Chemisch Pharmazeutische Forschungsgesellschaft Mbh | Heterocyclically-substituted 1-indole carboxamides as cyclo-oxygenase-2 inhibitors |
US5874430A (en) | 1996-10-02 | 1999-02-23 | Dupont Pharmaceuticals Company | 4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same |
EP0929533B1 (en) | 1996-10-02 | 2003-09-03 | Bristol-Myers Squibb Pharma Company | 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same |
EP0947507B1 (en) | 1996-12-18 | 2005-02-23 | Meiji Seika Kaisha Ltd. | Novel tetrahydrobenzindolone derivatives |
CA2292881A1 (en) | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
AR015425A1 (en) | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | BENZOTIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE FOR PREPARATION, INTERMEDIARY COMPOUNDS AND PROCEDURE FOR PREPARATION |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
WO1999044608A1 (en) | 1998-03-06 | 1999-09-10 | Astrazeneca Ab | New use |
EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
-
2000
- 2000-04-19 US US09/552,545 patent/US6380178B1/en not_active Expired - Fee Related
- 2000-05-01 JP JP2000615105A patent/JP2003518006A/en active Pending
- 2000-05-01 WO PCT/US2000/011846 patent/WO2000066225A1/en not_active Application Discontinuation
- 2000-05-01 EP EP00935851A patent/EP1173253A1/en not_active Withdrawn
- 2000-05-01 CA CA002368779A patent/CA2368779A1/en not_active Abandoned
- 2000-05-01 MX MXPA01011308A patent/MXPA01011308A/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733902A (en) * | 1987-10-01 | 1998-03-31 | Schering Aktiengesellschaft | Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors |
DE4330234A1 (en) * | 1993-09-02 | 1995-03-09 | Schering Ag | The use of progestogens and competitive progesterone antagonists for the production of pharmaceuticals for female fertility control and compositions comprising a progestogen and a competitive progesterone antagonist |
DE4344463A1 (en) * | 1993-12-22 | 1995-06-29 | Schering Ag | Combination product for contraception |
WO1996015794A1 (en) * | 1994-11-22 | 1996-05-30 | Balance Pharmaceuticals, Inc. | Compositions and methods for contraception and for treatment of benign gynecological disorders |
US5521166A (en) * | 1994-12-19 | 1996-05-28 | Ortho Pharmaceitical Corporation | Antiprogestin cyclophasic hormonal regimen |
US5693647A (en) * | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5696133A (en) * | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5696130A (en) * | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Tricyclic steroid receptor modulator compounds and methods |
WO1997049407A1 (en) * | 1996-06-25 | 1997-12-31 | Akzo Nobel N.V. | Progestogen-anti-progestogen regimens |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002020526A2 (en) * | 2000-09-07 | 2002-03-14 | Bayer Pharmaceuticals Corporation | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
WO2002020526A3 (en) * | 2000-09-07 | 2002-05-30 | Bayer Ag | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
US7071205B2 (en) | 2002-10-11 | 2006-07-04 | Ligand Pharmaceuticals Incorporated | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
US7084151B2 (en) | 2002-10-11 | 2006-08-01 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds |
Also Published As
Publication number | Publication date |
---|---|
CA2368779A1 (en) | 2000-11-09 |
EP1173253A1 (en) | 2002-01-23 |
JP2003518006A (en) | 2003-06-03 |
WO2000066225A8 (en) | 2002-05-30 |
MXPA01011308A (en) | 2005-10-05 |
US6380178B1 (en) | 2002-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6306851B1 (en) | Cyclocarbamate and cyclic amide derivatives | |
US6380235B1 (en) | Benzimidazolones and analogues | |
US6498154B1 (en) | Cyclic regimens using quinazolinone and benzoxazine derivatives | |
US6380178B1 (en) | Cyclic regimens using cyclocarbamate and cyclic amide derivatives | |
US6759408B2 (en) | Combination regimens using progesterone receptor modulators | |
US6369056B1 (en) | Cyclic urea and cyclic amide derivatives | |
US6319912B1 (en) | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides | |
US20020035099A1 (en) | Combination regimens using 3,3-substituted indoline derivatives | |
US6399593B1 (en) | Cyclic regimens using cyclic urea and cyclic amide derivatives | |
US6423699B1 (en) | Combination therapies using benzimidazolones | |
DE60013798T2 (en) | RECIPROCAL COMPOSITIONS CONTAINING THE PROGESTAGES AND PROGESTERONANT AGONISTS | |
EP1185535A1 (en) | Cyclocarbamate and cyclic amide derivatives | |
WO2000066592A1 (en) | Cyclic urea and cyclic amide derivatives | |
EP1173213A1 (en) | Compositions containing benzimidazolones and progestogens | |
CA2371642A1 (en) | Cyclic urea and cyclic amide derivatives | |
EP1173209A1 (en) | Contraceptive compositions containing 2,1-benzisothiazoline 2,2-dioxides and progestationals | |
EP1173211A1 (en) | Contraceptive compositions containing 3,3-substituted indoline derivatives and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00807137.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2000 615105 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2368779 Country of ref document: CA Ref document number: 2368779 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/011308 Country of ref document: MX Ref document number: 2000935851 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000935851 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 45/2000 UNDER (30) REPLACE "09/305007" BY "60/198246" |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000935851 Country of ref document: EP |